DARWINWEG 24, LEIDEN, P7
Market cap: $1.1B (3/23/2026)
Price: $15.97
Announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older
Reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow
Announces 2026 financial guidance and highlights rare disease pipeline at Investor Day
Receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS
Reports preliminary 2025 revenues and announces Investor Day
Reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow
Announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio
Provides update on previously announced G&A expense reduction plan
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities of Certain Foreign Private Issuers
Certificate
Effectiveness Notice
Registration of Securities
No filings found
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
SEC Staff Correspondence
Registration Statement for Depositary Shares
Submission Upload